Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62633
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients

AuthorsGutiérrez Valencia, Alicia; Martín-Peña, Reyes; Torres-Cornejo, Almudena; Ruiz-Valderas, Rosa; Castillo, J. R.; López-Cortés, Luis F. CSIC
Issue Date2012
PublisherOxford University Press
CitationJournal of Antimicrobial Chemotherapy 67(3): 681-684 (2012)
AbstractObjectives: To compare intracellular and plasma etravirine concentrations when etravirine was given at 200 mg/12 h versus 400 mg/24 h and to evaluate whether the results would support once-daily dosing.
Methods: This was an open-label sequential study in which eight patients on protease inhibitor (PI)-sparing regimens containing etravirine were included. Full pharmacokinetic profiles were performed while on 200 mg of etravirine/12 h and after switching to 400 mg of etravirine/24 h. Intracellular and plasma levels were determined by liquid chromatography coupled with mass spectrometry. Pharmacokinetic parameters were calculated by non-compartmental analysis and compared by geometric mean ratios (GMRs) using 200 mg of etravirine/12 h as the reference group. Trial registration: ClinicalTrials.gov NCT01121809.
Results: The geometric mean (GM) for etravirine AUC 0-ο (5602 versus 5076 ng ·h/mL, GMR 0.91), C max (403 versus 495 ng/mL, GMR 1.23) and C min (139 versus 102 ng/mL, GMR 0.74) were similar with both dosing schedules at the intracellular level. In plasma, the GMRs for AUC 0-ο, C max and C min were 1.31, 1.76 and 0.99, respectively. The mean intracellular penetration, evaluated as intracellular and plasma AUC 0-ο ratios, was 81% when etravirine was dosed twice daily and 56% with once-daily dosing.
Conclusions: Our results show that intracellular etravirine levels were similar with both dosing regimens in patients with PI-sparing regimens, while etravirine plasma AUC 0-ο and C max were 30% and 76% higher with the once-daily regimen, respectively. Thus, a once-daily dosing regimen is supported not only by plasma etravirine pharmacokinetic profiles but also by intracellular levels. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
URIhttp://hdl.handle.net/10261/62633
DOI10.1093/jac/dkr534
Identifiersdoi: 10.1093/jac/dkr534
issn: 0305-7453
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

SCOPUSTM   
Citations

9
checked on May 15, 2022

WEB OF SCIENCETM
Citations

10
checked on May 9, 2022

Page view(s)

280
checked on May 17, 2022

Download(s)

67
checked on May 17, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.